Fusion Pharmaceuticals has now raised $171m altogether to deliver cancer radiopharmaceuticals based on McMaster University research.

GV and Nextech are among the participants in a series A round that is funding the launch of EQRx, which is developing cheaper copies of existing drugs.

The cash-and-share transaction will allow iRobot to exit the telehealth technology developer eight years after it paid $6m for a minority stake.

Canada Pension Plan Investment Board has pledged up to $20m for the Varian Medical and Johnson & Johnson-backed oncology drug developer.

Eli Lilly-backed ReadCoor took its total funding to $50m and will use the funding to commercialise its gene sequencing technology.

GV-backed solid tumour treatment developer Pact Pharma has completed an oversubscribed $75m series C round led by Vida Ventures.

Subsidiaries of Astellas and Novartis co-led a round featuring GV and 6 Dimensions Capital that took the cancer drug developer's overall funding to $60m.

Wilson Sonsini Goodrich & Rosati has invested in genomic sequencing amplification startup BioSkryb as part of an $11.5m round.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Jasper Therapeutics, based in part on Stanford research, has raised a $15m series A extension on the back of early clinical results from its blood transplant conditioning program.